Discovery of Selective Cannabinoid CB₂ Receptor Agonists by High-Throughput Screening.

Area of Science:

• Pharmacology
• Immunology
• Neuroscience

Background:

• The endocannabinoid system (ECS) regulates vital physiological functions, including mood, appetite, immune response, and pain.
• Current drug development targeting cannabinoid receptors (CB1 and CB2) faces challenges due to CB1's psychoactive side effects.
• CB2 receptors, primarily in immune cells, offer a promising target for peripheral modulation without central nervous system side effects.

Purpose of the Study:

• To discover selective agonists or positive allosteric modulators (PAMs) of the CB2 receptor through high-throughput screening.
• To identify novel compounds for therapeutic development targeting the ECS.
• To find potential treatments for immune modulation and pain management with improved safety profiles.

Main Methods:

• Conducted a high-throughput screen to identify CB2 receptor modulators.
• Characterized identified compounds for selectivity against CB1 and CB2 receptors.
• Evaluated compounds for potential therapeutic applications in pain and immune modulation.

Main Results:

• Identified 167 CB2 agonists.
• No CB2 positive allosteric modulators (PAMs) were discovered.
• Two compounds demonstrated high selectivity for CB2 over CB1 receptors.

Conclusions:

• The study expands drug discovery options for the endocannabinoid system.
• Identified CB2 agonists offer potential for novel therapies.
• Selectivity for CB2 may lead to treatments with reduced adverse effects.